Latest News & Updates

Breaking News

15 hours ago
Team Pharma Now

What to Expect at India Pharma Expo 2026: India’s Top Pharma Industry Convergence

IDEAYA Enrolls First Patient In Phase 1 Trial Of IDE034 Bispecific TOP1 Antibody-Drug Conjugate (ADC),Triggers $5M Biocytogen Milestone

Vaibhavi M.

Novartis To Establish Texas Radioligand Therapy Manufacturing Site, Expands Network With New Denton Facility

Vaibhavi M.

Hikma Launches Authorised Generic Version Of Nucynta In The US, Expands Generics Portfolio

Vaibhavi M.

FDA Approves Merck Animal Health’s NUMELVI For Canine Allergic Dermatitis, Atinvicitinib Becomes First Second-Gen JAK Inhibitor For Itch In Dogs

Vaibhavi M.

Other trending news you may like to read

What to Expect at India Pharma Expo 2026: India’s Top Pharma Industry Convergence

India Pharma Expo 2026 arrives April 23–25 at HITEX, uniting 15K+ attendees, 300+ exhibitors for smart manufacturing, biosimilars, and NextGen Pharma Awards.

Team Pharma Now

IDEAYA Enrolls First Patient In Phase 1 Trial Of IDE034 Bispecific TOP1 Antibody-Drug Conjugate (ADC),Triggers $5M Biocytogen Milestone

IDEAYA doses first patient in Phase 1 IDE034 bispecific TOP1 ADC trial.

Vaibhavi M.

Novartis To Establish Texas Radioligand Therapy Manufacturing Site, Expands Network With New Denton Facility

Novartis to build Texas RLT plant, expanding US oncology manufacturing.

Vaibhavi M.

Hikma Launches Authorised Generic Version Of Nucynta In The US, Expands Generics Portfolio

Hikma launches authorised generic Nucynta (tapentadol) in US pain market.

Vaibhavi M.